CD274 and lung cancer: Durvalumab, a PD-L1 inhibitor, as an adjuvant treatment following definitive CRT for unresectable stage III NSCLC, has the most robust evidence of survival benefits among combination therapies of radiotherapy and immunotherapy for lung cancer.